Introduction {#section1-1559325819889814}
============

Colorectal cancer (CRC) remains an important global health problem and may lead to 1.4 million new cancer cases every year and 700 000 cancer-related deaths worldwide. The incidence and death rate of CRC have been increasing in China.^[@bibr1-1559325819889814]^ Radical surgical intervention remains the primary treatment for CRC.^[@bibr2-1559325819889814]^ Nevertheless, approximately 25% of patients with CRC develop recurrence or distant metastasis.^[@bibr3-1559325819889814]^ The overall prognosis of CRC remains poor, with 50% estimated 5-year survival.^[@bibr4-1559325819889814]^ Therefore, better understanding of carcinogenic mechanisms and the use of ideal cancer biomarkers can promote the diagnosis and prognosis of CRC.

There is a well-documented correlation between inflammation and cancer, although the exact mechanism is still not fully understood. It has been reported that cancer-associated inflammation can increase the risk of tumor development and angiogenesis.^[@bibr5-1559325819889814]^ Tumor-associated inflammatory response consists of inflammatory cells and a range of inflammatory mediators.^[@bibr6-1559325819889814]^ Systemic inflammatory scoring systems, such as the albumin to globulin ratio, the neutrophil to lymphocyte ratio (NLR), the platelet to lymphocyte ratio, and the lymphocyte to monocyte ratio (LMR), have been reported in many solid tumors as prognostic markers.^[@bibr7-1559325819889814][@bibr8-1559325819889814]-[@bibr9-1559325819889814]^ As a new inflammation-based scoring index, combination of C-reactive protein (CRP) and albumin, has been reported continuously in recent years. The C-reactive protein to albumin ratio (CAR) has been widely investigated for their value in predicting prognosis of patients with CRC.^[@bibr9-1559325819889814],[@bibr10-1559325819889814]^ However, the prognostic value of CAR in CRC remains controversial.^[@bibr11-1559325819889814],[@bibr12-1559325819889814]^ For example, Climent et al^[@bibr11-1559325819889814]^ found that there was no significant difference in both overall survival (OS) and disease-free survival (DFS) between the high- and low-CAR groups (*P* = .12 and .33, respectively). Thus, the purpose of this meta-analysis is to assess the relationship of pretreatment CAR with the prognosis and clinicopathology of patients with CRC.

Materials and Methods {#section2-1559325819889814}
=====================

Search Strategy {#section3-1559325819889814}
---------------

Relevant studies were performed through MEDLINE, Embase, and Cochrane Library databases up to March 20, 2019. The following search terms were used: ("C-reactive protein to Albumin ratio" or "C-reactive protein-to-Albumin ratio" or "C-reactive protein Albumin ratio" or "C-reactive protein/Albumin ratio" or "CRP/Alb ratio") and ("colorectal cancer" or "colorectal carcinoma" or "colorectal tumor" or "colorectal neoplasms" or "colon cancer" or "rectal cancer" or "CRC"). Detailed search strategies refer to supplemental materials.

Inclusion and Exclusion Criteria {#section4-1559325819889814}
--------------------------------

Published articles were selected for study based on the following inclusion criteria: (1) studies reporting the association between pretreatment CAR and prognosis in CRC; (2) patients did not receive any treatment (such as surgery or chemotherapy) before obtaining samples; and (3) the study provided sufficient information for extraction or calculation of the individual hazard ratio (HR) or odds ratio (OR) and associated 95% confidence intervals (CIs). The criteria for exclusion of studies were as follows: (1) studies did not include any survival outcomes, (2) duplicate publications, and (3) reviews, meta-analysis, letters, and conference abstracts.

Data Extraction {#section5-1559325819889814}
---------------

Two reviewers independently reviewed articles for inclusion/exclusion qualifications. The following information was extracted: study details (first author, year and country of study, sample size, and number of patients involved and distribution of age and gender), pathological characteristics (tumor diameter, differentiation, tumor node metastasis \[TNM\] stage, and lymphatic invasion and venous invasion), and clinical features (type of treatment applied, CAR cutoff values, carcinoembryonic antigen \[CEA\] and carbohydrate antigen 19-9 \[CA19-9\] level, patient's survival outcome, and duration of follow-up period).

Quality Assessment {#section6-1559325819889814}
------------------

In this meta-analysis, the quality assessment for the nonrandomized studies was evaluated by 2 reviewers independently based on the Newcastle-Ottawa quality assessment scale (NOS).^[@bibr13-1559325819889814]^ In this scale, studies were awarded a maximum score of 9 points; studies with NOS values greater than 6 are considered high quality studies.

Statistical Analysis {#section7-1559325819889814}
--------------------

We used Stata version 13.0 (StataCorp, College station, Texas) to pool HRs for OS, progression-free survival, and ORs for clinicopathological parameters. In this meta-analysis, the HRs and 95% CIs were directly extracted if a study reported the survival analysis, otherwise, they were computed from the Kaplan-Meier graph by using the software of Engauge Digitizer (version 4.1).^[@bibr14-1559325819889814],[@bibr15-1559325819889814]^ The heterogeneity among the eligible studies was calculated by the Cochran Q-test and I^2^ statistic. If I^2^ ≤ 50% or *P* \> .05 indicated low heterogeneity, we used fixed-effect models by using inverse variance method. Otherwise, we used random-effect models using the DerSimonian and Laird method, which considers both within-study and between-study variations.^[@bibr16-1559325819889814]^ We did sensitivity analyses in order to validate the robustness of the pooled results by removing each study. Publication bias was evaluated using Begg and Egger tests and defined significantly at a *P* value \<.05.^[@bibr17-1559325819889814],[@bibr18-1559325819889814]^

Results {#section8-1559325819889814}
=======

Study Selection {#section9-1559325819889814}
---------------

Literature research identified 45 records: 16 from Medline, 13 from Embase, and 16 from Cochrane Library. As shown in the flow diagram ([Figure 1](#fig1-1559325819889814){ref-type="fig"}), 36 articles were left after removing duplications. After screening titles and abstracts, 15 full-text articles remained for further assessment, and 6 articles were excluded according to the inclusion criteria. In the final, a total of 9 articles involving 3431 patients were eligible for quantitative synthesis.^[@bibr9-1559325819889814],[@bibr11-1559325819889814],[@bibr12-1559325819889814],[@bibr19-1559325819889814][@bibr20-1559325819889814][@bibr21-1559325819889814][@bibr22-1559325819889814][@bibr23-1559325819889814]-[@bibr24-1559325819889814]^

![Flow diagram of study retrieval and selection processes.](10.1177_1559325819889814-fig1){#fig1-1559325819889814}

Study Characteristics {#section10-1559325819889814}
---------------------

All included studies were published from 2016 to 2019. Among them, 6 studies were from Japan and 1 each from China, the United Kingdom, and Ireland. There were 6 studies reported at mixed disease, and 3 studies reported in metastatic disease. The eligible articles consisted of the following: 9 on OS and 5 on DFS/RFS. In addition, prognostic data were directly retrieved from 6 studies on OS or DFS/RFS. Cutoff values of CAR ranged from 0.0271 to 0.65. The HR and 95% CI data were evaluated using univariate analysis in 4 studies and multivariate analysis in 5 studies. The NOS scores ranged from 6 to 9 stars and were all regarded as high quality. The detailed characteristics of the eligible articles are presented in [Table 1](#table1-1559325819889814){ref-type="table"}.

###### 

Characteristics of the Studies Included in the Meta-Analysis.

![](10.1177_1559325819889814-table1)

  Author            Year   Country          Location   Sample Size   Age (years)   Treatment      Stage        Cutoff Value   Outcome   Analysis   Confounding Variables                                                                                         NOS Score
  ----------------- ------ ---------------- ---------- ------------- ------------- -------------- ------------ -------------- --------- ---------- ------------------------------------------------------------------------------------------------------------- -----------
  Ide et al         2017   Japan            Rectum     115           64 (33-83)    Mixed          Mixed        0.049          OS/DFS    MV         TNM stage, vascular invasion, CEA, mGPS                                                                       7
  Ishizuka et al    2016   Japan            CRC        627           NA            Surgery        Mixed        0.038          OS        MV         Gender, tumor size, tumor type, Grade, WBC count, platelet count, CEA, CA19-9, NLR, GPS, stage                9
  Tominaga et al    2016   Japan            CRC        136           NA            Mixed          Metastatic   0.1            OS/DFS    UV                                                                                                                       7
  Chen et al        2017   China            CRC        163           55 (15-81)    Mixed          Mixed        0.132          OS        UV                                                                                                                       8
  Shibutani et al   2019   Japan            CRC        40            NA            Chemotherapy   Metastatic   0.122          OS/PFS    MV         Age, gender, PS, site, No. of prior regimens, RAS status, No. of metastasis, combined targeted therapy, LDH   8
  Shibutani et al   2016   Japan            CRC        705           68 (26-90)    Surgery        Mixed        0.0271         OS/RFS    MV         T stage, tumor size, lymphatic involvement, venous involvement, LNM                                           7
  Dolan et al       2018   United Kingdom   Colon      801           NA            Mixed          Mixed        0.22           OS/CSS    MV         TNM stage, NLR, NLS, PLR, PLS, LMR, LMS, NPS, mGPS                                                            7
  Climent et al     2019   Ireland          CRC        804           69.9 ± 12.3   Mixed          Mixed        0.464          OS/DFS    UV                                                                                                                       7
  Ikeguchi et al    2017   Japan            CRC        40            68 (35-94)    Chemotherapy   Metastatic   0.65           OS        UV                                                                                                                       6

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRC, colorectal cancer; CSS, cancer-specific survival; DFS, disease-free survival; GPS, Glasgow Prognostic Score; LDH, lactate dehydrogenase; LMR, lymphocyte--monocyte ratio; LMS, lymphocyte--monocyte score; LNM, lymph node metastasis; mGPS, modified Glasgow prognosis score; MV, multivariate; NA, not available; NLR neutrophil--lymphocyte ratio; NLS neutrophil--lymphocyte score; NPS, neutrophil--platelet score; NOS, Newcastle-Ottawa quality assessment scale; OS, overall survival; PFS, progression-free survival; PLR, platelet--lymphocyte ratio; PLS, platelet--lymphocyte score; PS, performance status; RAS, RAS type GTPase family status; RFS, relapse-free survival; TNM, tumor node metastasis; UV, univariate; WBC, white blood cell.

Meta-Analysis {#section11-1559325819889814}
-------------

### C-reactive protein to albumin ratio and OS in CRC {#section12-1559325819889814}

All included studies involving 3431 patients reported the predicting role of pretreatment CAR for OS. [Figure 2](#fig2-1559325819889814){ref-type="fig"} showed that elevated pretreatment CAR was predictive of a short OS (pooled HR: 2.18, 95% CI: 1.70-2.78, *P* \< .001). Furthermore, subgroup analysis was performed to further explore the prognostic value of CAR in CRC ([Table 2](#table2-1559325819889814){ref-type="table"}). The pooled HRs for most subgroups were not significantly altered by the study characteristics. Exploratory subgroup analysis, based on tumor stage, indicated that patients with mixed stage (pooled HR: 2.07; 95% CI = 1.59-2.69; *P* \< .001) and metastatic stage (pooled HR: 3.41; 95% CI = 1.63-7.12; *P* \< .001) were all significantly associated with worse OS. Similarly, stratified analysis by cutoff for CAR showed that significant relationship between elevated CAR and shorter OS was detected in patients with CAR ≥ 0.1 (pooled HR: 1.89; 95% CI = 1.57-2.28; *P* \< .001) and patients with CAR \< 0.1 (pooled HR: 2.61; 95% CI = 1.51-4.53; *P* = 0.001). Moreover, the region, sample size, treatment, and analysis method also did not affect the significant predictive value of CAR in patients with CRC.

![Forest plot of the correlation between CAR and OS in patients with colorectal cancer. CAR indicates C-reactive protein to albumin ratio; OS, overall survival.](10.1177_1559325819889814-fig2){#fig2-1559325819889814}

###### 

Pooled HRs for OS According to Subgroup Analyses.

![](10.1177_1559325819889814-table2)

  Subgroup         No. of Studies   No. of Patients   HR (95% CI)         *P* Value   Heterogeneity   
  ---------------- ---------------- ----------------- ------------------- ----------- --------------- -------
  Overall          9                3431              2.18 (1.70-2.78)    \<.001      28.8            0.189
  Region                                                                                              
   Asia            7                1826              2.49 (1.74-3.58)    \<.001      33.4            0.173
   Europe          2                1605              1.84 (1.51-2.25)    \<.001      0               0.979
  Sample size                                                                                         
   ≥300            4                2937              3.10 (1.70-5.32)    \<.001      36.1            0.181
   \<300           5                494               1.91 (1.60-2.27)    \<.001      0               0.562
  Stage                                                                                               
   Mixed           6                3215              2.07 (1.59-2.69)    \<.001      37.4            0.157
   Metastatic      3                216               3.41 (1.63-7.12)    .001        0               0.546
  Cutoff for CAR                                                                                      
   \<0.1           3                1447              2.61 (1.51-4.53)    .001        63.3            0.066
   ≥0.1            6                1984              1.89 (1.57-2.28)    \<.001      0               0.541
  Treatment                                                                                           
   Surgery         2                1332              2.11 (1.36-3.26)    .001        37.3            0.207
   Mixed           5                2019              2.09 (1.46-2.97)    \<.001      35.3            0.186
   Chemotherapy    2                80                4.32 (1.76-10.64)   .001        0               0.530
  Analysis                                                                                            
   Univariate      4                1143              1.95 (1.24-3.05)    .004        0               0.670
   Multivariate    5                288               2.39 (1.65-3.46)    \<.001      58.5            0.047

Abbreviations: CAR, C-reactive protein to albumin ratio; CI, confidence interval; HR, hazard ratio.

### C-reactive protein to albumin ratio and DFS/RFS in CRC {#section13-1559325819889814}

Five studies involving 1800 patients investigated the correlation between pretreatment CAR and DFS/RFS. Similar to the merge of HRs for OS, as shown in [Figure 3](#fig3-1559325819889814){ref-type="fig"}, the pooled HR of CAR indicated that elevated CAR was associated with decreased DFS/RFS (pooled HR: 2.36, 95% CI: 1.40-3.98, *P* \< .001).

![Forest plot of the correlation between CAR and DFS/RFS in patients with colorectal cancer. CAR indicates C-reactive protein to albumin ratio; DFS, disease-free survival; RFS, relapse-free survival.](10.1177_1559325819889814-fig3){#fig3-1559325819889814}

### C-reactive protein to albumin ratio and clinicopathological characteristics {#section14-1559325819889814}

A total of 10 variables were investigated in the meta-analysis, including age, gender, tumor location, tumor diameter, differentiation, TNM stage, CEA level, CA19-9 level, lymphatic invasion, and venous invasion. The results demonstrated that elevated CAR was related to gender (male vs female; OR = 1.71, 95% CI: 1.30-2.24, *P* \< .001), tumor diameter (≥ 50 mm vs \< 50 mm; OR = 3.69, 95% CI: 2.61-5.21, *P* \< .001), TNM stage (III-IV vs I-II; OR = 3.45, 95% CI: 1.76-6.77, *P* \< .001), CEA (\> 8.7 ng/mL vs \<8.7 ng/mL; OR = 3.70, 95% CI: 2.51-5.47, *P* \< .001), CA19-9 (\>9.5 ng/mL vs \<9.5 ng/mL; OR = 1.89, 95% CI: 1.37-2.60, *P* \< .001), lymphatic invasion (yes vs no; OR = 1.29, 95% CI: 1.02-1.64, *P* = .03), and venous invasion (yes vs no; OR = 1.37, 95% CI: 1.04-1.81, *P* = .03). However, no obvious association was found between the CAR and age (\>median vs \<median; OR = 1.73, 95% CI: 0.84-3.56, *P* = .14), tumor location (left vs right; OR = 1.34, 95% CI: 0.33-5.42, *P* = .68), and differentiation (low vs moderate/high; OR = 1.51, 95% CI: 1.00-2.27, *P* = .05). The details of the relationship between CAR and clinicopathologic parameters are summarized in [Table 3](#table3-1559325819889814){ref-type="table"}.

###### 

Meta-Analysis of the Association Between CAR and Clinicopathological Features of CRC.

![](10.1177_1559325819889814-table3)

  Characteristics                          No. of Studies   No. of Patients   OR (95% CI)        *P*      Heterogeneity   
  ---------------------------------------- ---------------- ----------------- ------------------ -------- --------------- -------
  Age (\>median vs \<median)               3                830               1.73 (0.84-3.56)   .14      67              0.05
  Gender (male vs female)                  4                966               1.71 (1.30-2.24)   \<.001   0               0.57
  Tumor location (left vs right)           3                339               1.34 (0.33-5.42)   .68      83              0.003
  Tumor diameter (≥50 mm vs \<50 mm)       1                627               3.69 (2.61-5.21)   \<.001   \-              \-
  Differentiation (low vs moderate/high)   3                1468              1.51 (1.00-2.27)   .05      0               0.90
  TNM stage (III-IV vs I-II)               1                163               3.45 (1.76-6.77)   \<.001   \-              \-
  CEA (\>8.7 ng/mL vs \<8.7 ng/mL)         1                627               3.70 (2.51-5.47)   \<.001   \-              \-
  CA19-9 (\>9.5 ng/mL vs \<9.5 ng/mL)      1                627               1.89 (1.37-2.60)   \<.001   \-              \-
  Lymphatic invasion (yes vs no)           3                1468              1.29 (1.02-1.64)   .03      43              0.17
  Venous invasion (yes vs no)              3                1468              1.37 (1.04-1.81)   .03      0               0.43

Abbreviations: CAR, C-reactive protein to albumin ratio; CA19-9, carbohydrate antigen 19-9; CRC, colorectal cancer; CEA, carcinoembryonic antigen; CI, confidence interval; OR, odds ratio; TNM, tumor node metastasis.

Sensitivity Analysis and Publication Bias {#section15-1559325819889814}
-----------------------------------------

Sensitivity analyses were conducted to estimate the stability of CAR for OS and DFS/RFS. The results showed that no noteworthy influence was detected after removing any single study, which indicated that our conclusions were reliable ([Figures 4](#fig4-1559325819889814){ref-type="fig"} and [5](#fig5-1559325819889814){ref-type="fig"}). As shown in [Figure 6](#fig6-1559325819889814){ref-type="fig"}, there was no significant publication bias in OS (*P* = .061 for Begg test and *P* = .115 for Egger test).

![Sensitivity analysis of CAR on OS in patients with CRC. CAR indicates C-reactive protein to albumin ratio; CRC, colorectal cancer; OS, overall survival.](10.1177_1559325819889814-fig4){#fig4-1559325819889814}

![Sensitivity analysis of CAR on DFS/RFS in patients with CRC. CAR indicates C-reactive protein to albumin ratio; CRC, colorectal cancer; DFS, disease-free survival; RFS, relapse-free survival.](10.1177_1559325819889814-fig5){#fig5-1559325819889814}

![Begg funnel plot of publication bias test for OS in patients with CRC. CRC indicates colorectal cancer; OS, overall survival.](10.1177_1559325819889814-fig6){#fig6-1559325819889814}

Discussion {#section16-1559325819889814}
==========

Current systematic review and meta-analysis including 3134 patients with CRC give solid evidence of an association between elevated pretreatment CAR and worse prognosis. When stratified by region, sample size, tumor stage, cutoff value for CAR, treatment, and analysis method, the results remained constant. Moreover, elevated pretreatment CAR was correlated with advanced clinicopathological characteristics, such as large tumor diameter, advanced tumor stage, high CEA and CA19-9 levels, and positive lymphatic and venous invasion. Therefore, CAR could serve as a biomarker for the prognosis of patients with CRC.

It is well recognized that inflammation is an important factor in the development of tumor. Inflammatory response can promote tumorigenesis and progression by affecting the tumor microenvironment.^[@bibr6-1559325819889814]^ Tumor-associated inflammatory responses lead to the release of a variety of mediators, such as acute phase proteins, chemokines, and cytokines, which stimulate tumor cell growth, promote angiogenesis, resist cell death and apoptosis, and enhance invasion ability of tumor cells.^[@bibr5-1559325819889814],[@bibr25-1559325819889814]^ There is increasing evidence that high levels of systemic inflammatory cells have the potential to serve as diagnostic or prognostic markers in patients with CRC.^[@bibr9-1559325819889814],[@bibr26-1559325819889814][@bibr27-1559325819889814]-[@bibr28-1559325819889814]^ Patel et al^[@bibr29-1559325819889814]^ found an correlation between high systemic inflammatory response and right-sided CRC, assessed using modified Glasgow prognosis score, NLR, and LMR. Yang et al^[@bibr30-1559325819889814]^ have shown that elevated NLR is indicative of a poor prognosis for patients with CRC receiving neoadjuvant chemoradiotherapy.

As an inflammatory marker, the CAR was calculated from the serum CRP and albumin levels; CAR was originally studied as a prognostic marker for patients with sepsis^[@bibr31-1559325819889814]^ and was later used as a marker for patients with tumors.^[@bibr32-1559325819889814]^

Recently, CAR has been developed to predict oncological outcomes in patients with CRC. However, the exact mechanism regarding its prognostic ability have not been clearly elaborated. C-reactive protein is an acute-phase protein that is synthesized in the liver, together with cytokines such as interleukin (IL) 1, IL-6, and tumor necrosis factor α.^[@bibr33-1559325819889814],[@bibr34-1559325819889814]^ Research has discovered that CRP can produce inflammatory cytokines and chemokines, which leading to tumor progression.^[@bibr35-1559325819889814]^ Several studies have shown that elevated CRP level was associated with poor prognosis of patients withCRC.^[@bibr36-1559325819889814],[@bibr37-1559325819889814]^ Albumin is the most abundant plasma protein, accounting for about 50% of the total protein content. It is the most commonly used indicator of the nutritional status and is also involved in inflammatory response which acts as an acute-phase protein.^[@bibr38-1559325819889814]^ Hypoalbuminemia caused by a condition under suppressed production of albumin results in activation of cytokines such as IL-1, IL-6, and tumor necrotic factor α.^[@bibr39-1559325819889814],[@bibr40-1559325819889814]^ Thus, CAR may represent a balance between the inflammation and nutritional status, and an increased CAR indicates a poor prognosis.

Several limitations of this study should be considered. First, most of included studies included are carried out in Asian countries, more cohort studies from other regions are necessary. Second, the cutoff value of CAR applied in the enrolled studies was not uniform. Third, part of the HRs and 95% CIs could not be directly obtained and were estimated by software, which may reduce the overall accuracy of the combined results. Finally, this meta-analysis included the predominance of retrospective studies and lacked random control test studies, and the retrospective studies may bring confounding variables.

Conclusions {#section17-1559325819889814}
===========

Our study suggested that elevated pretreatment CAR may serve as a promising indicator for prognostic evaluation of patients with CRC.

Supplemental Material {#section18-1559325819889814}
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